REFRACTORY ACUTE MYELOID LEUKEMIA

This early-stage trial tests whether adding regorafenib to the standard venetoclax plus azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 20 participants will receive the combination…

This study tests a combination of two drugs, venetoclax and decitabine, in 20 adults with acute myeloid leukemia that has returned or not responded to prior therapy. The goal is to see if the combo can shrink or control the cancer and help patients move toward a stem cell transpl…

This study tests adding the targeted drug sorafenib to standard chemotherapy (busulfan and fludarabine) before a donor stem cell transplant for adults with acute myeloid leukemia that has returned or not responded to treatment. The goal is to find the safest dose of sorafenib and…

This early-stage trial tests the safety and best dose of TAK-243 in about 42 adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or are not responding to standard therapy. TAK-243 works by blocking enzymes that cancer cells need to grow. The study i…

This early-stage study tests a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. AOH1996 works by blocking a protein that helps cancer…

This early-stage study tests a drug called palbociclib, given alone or with other medicines (sorafenib, decitabine, or dexamethasone), in 32 adults whose leukemia has returned or not responded to prior therapy. The main goal is to find the safest dose and check for side effects. …

This study tests a combination of two drugs, nintedanib and azacitidine, in older adults with a type of leukemia called AML who cannot have or do not want standard intensive chemotherapy. The goal is to find the best dose of nintedanib when given with azacitidine and to see what …

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work by b…

This study tests a drug called enasidenib in children and young adults (ages 2 to 21) with acute myeloid leukemia that has returned or not responded to treatment. Participants must have a specific genetic change (IDH2 mutation). The goal is to see if the drug is safe and how the …

This early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…

This early-phase trial tests a new drug called M3814 combined with three chemotherapy drugs (MEC) in 48 adults whose acute myeloid leukemia has returned or not responded to treatment. The goal is to find the best dose and check for side effects. The study is active but no longer …

This study tests a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia that has worsened. The goal is to see how many patients achieve remission after two trea…

This early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in adults with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…

This early-stage trial tests a new drug, 8-chloro-adenosine, combined with venetoclax in 30 adults whose acute myeloid leukemia has returned or not responded to prior therapy. The main goal is to find the safest dose and check for side effects. The study is currently on hold.

This early-stage study tests the safety and best dose of two drugs, selinexor and venetoclax, when given with standard chemotherapy to children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 37 participants will receive the c…

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with two standard drugs, decitabine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find the safest dose and understand…

This study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…

This early-phase trial is testing a drug called flotetuzumab in children, adolescents, and young adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The drug works by helping the body's immune cells recognize and attack leukemia cells. T…

This early-stage trial tests a combination of two drugs—entrectinib and ASTX727—in adults with acute myeloid leukemia (AML) that has returned or not responded to treatment and has a specific genetic change (TP53 mutation). The goal is to find the safest dose and see if the combin…

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted antibody (gemtuzumab ozogamicin) in about 50 adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatment. The goal is to see if the co…

This study tests a drug called olaparib in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has returned or not responded to treatment and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to grow. The…

This early-phase study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells that are genetically modified to recognize and attack cancer cells ca…

This study tests a new combination of three drugs (navitoclax, venetoclax, and decitabine) in people with acute myeloid leukemia that has returned or stopped responding after prior treatment with venetoclax. The main goal is to find the safest dose and understand side effects. Ab…